Enliven Therapeutics (NASDAQ:ELVN) vs. NLS Pharmaceutics (NASDAQ:NCEL) Head-To-Head Comparison

NLS Pharmaceutics (NASDAQ:NCEL) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for NLS Pharmaceutics and Enliven Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1	0	0	0	1.00
Enliven Therapeutics	1	0	5	0	2.67

Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 133.69%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than NLS Pharmaceutics.

Insider & Institutional Ownership

95.1% of Enliven Therapeutics shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares NLS Pharmaceutics and Enliven Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A
Enliven Therapeutics	N/A	N/A	-$89.02 million	($2.00)	-8.82

Risk & Volatility

NLS Pharmaceutics has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares NLS Pharmaceutics and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Enliven Therapeutics	N/A	-29.15%	-27.88%

Summary

Enliven Therapeutics beats NLS Pharmaceutics on 6 of the 9 factors compared between the two stocks.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.